The Baveno Cooperation: an EASL Consortium

Overview on published/presented data on MASH cirrhosis #LiverSky @bavenocoop.bsky.social

🖇️: authors.elsevier.com/sd/article/S...

🚨 Join us for the VALDIG PSVD Meeting – a 2-day event dedicated to PSVD!

🗓️ Dec 4–5, 2025
📍 CNAM, Paris 🇫🇷
💳 Onsite €150 (payment after reg.) | Online free
👉Organized by EURO-VALDIG NET & FILFOIE

Register here ➡️ app.evalandgo.com/f/325218/4qE...

Program 👇

🔎Around 1 in 4 people with CCA have chronic liver diseases, and 1 in 10 have cirrhosis.
Read more here: ❇️ ow.ly/GIh450X2qc0

Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal

The New England Journal of Medicine Apixaban for Extended Treatment of Provoked Venous Thromboembolism A Research Summary based on Piazza G et al. | 10.1056/NEJMoa2509426 | Published on August 30, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary: nej.md/4p6tIDo

Interaction of inflammation and portal hypertension in cirrhosis progression Nature Reviews Gastroenterology & Hepatology, Published online: 29 September 2025; doi:10.1038/s41575-025-01107-2Portal hypertension and systemic inflammation are key factors driving decompensation and organ failure in cirrhosis. This Review examines those two factors and, based on their mechanistic interaction, proposes a new concept of the clinical phenotypes in decompensated cirrhosis.

New online! Interaction of inflammation and portal hypertension in cirrhosis progression

The list of societies and journals remembering Prof. Jaume Bosch increases…

🇪🇸 REED: reed.es/prof-jaume-b...
🌍 The Lancet: thelancet.com/journals/lan...

The Baveno VIII Meeting (27–28 March 2026) will be a special occasion to honour his memory.
Registration: baveno8.org/registration/

If you are interested in portal hypertension and like to hear from all disciplines involved, this is the conference for you 👇🏼

Thank you for the invitation and the opportunity to review HRS-AKI and ascites management.

#liversky
@portal360mtg.bsky.social
@bavenocoop.bsky.social

🚨 Mark your calendars! Baveno VIII Meeting → 27–28 March 2026

Reminder from @crisripoll.bsky.social, Baveno Vice-Secretary at #DGVS

⏳ only 6 months left!

Register 👉 bavenocoop.net

@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension

👀 at our auditorium

🙏 incredible hospitality

👉 See our 🇯🇵 friends at Baveno VIII

Muere Jaume Bosch, hepatólogo y expresidente de la AEEH entre 2013 y 2015 Fue el primer director científico del Ciber de Enfermedades Hepáticas y Digestivas

Press
🗞️Redacción Médica: redaccionmedica.com/secciones/me...
🗞️Diario Médico: diariomedico.com/medicina/apa...
📰La Razón: larazon.es/cataluna/fal...
⚽️ Lagrada: lagradaonline.com/espanyol-due...

May his legacy continue to inspire, heal, and guide the future of hepatology. 🌿

In Memoriam: Professor Jaume Bosch (1947–2025) - CASL - Canadian Association for the Study of the Liver A giant in both humanity and science, Jaume was an extraordinary mentor and role model to countless physicians and researchers […]

🇨🇦 hepatology.ca/2025/07/17/i...
🇧🇷 sbhepatologia.org.br/noticias/not...
🇮🇹 AISF: dldjournalonline.com/action/showP...

Institutions
🏥Hospital Clínic / IDIBAPS: clinicbarcelona.org/en/news/deat...
🏛️CIBEREHD: ciberisciii.es/noticias/lam...

The passing of Prof. Jaume Bosch (1947–2025) has generated, and continues to generate, heartfelt tributes

Here you can read some of them:

Scientific societies
🇪🇺EASL: journal-of-hepatology.eu/action/showP...
🇪🇸AEEH: aeeh.es/obituario-ja...
🇨🇭SASL: sasl.unibas.ch/files/mixed%...

Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial) There is no evidence of a difference between carvedilol 12.5 mg daily and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. ....

🔗 Full paper: doi.org/10.1111/apt....

📝 Editorial by @reibergerthomas.bsky.social and Benedikt Simbrunner:
onlinelibrary.wiley.com/doi/epdf/10....

#LiverTwitter

Some evidence on role of Simvastatin and Carvedilol in patients after variceal🩸. Stage of cirrhosis and right combination may b the 🔑 for statins in PHTN
#LiverSky. @easlnews.bsky.social @bavenocoop.bsky.social @amcollegegastro.bsky.social @aasldnews.bsky.social

journals.lww.com/ajg/abstract...

Editor's Essential Reading ➡️

A review of the diagnosis and management of hemochrojmatosis, a genetic iron overload disease that is under diagnosed and treatable

Learn more: ow.ly/NIl350WuZoz

Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study Previous studies suggested that anticoagulation decreases the probability of developing portal hypertension (PHT)-related complications and improves survival in cirrhotic patients. Our study aimed to ...

CIRROXABAN Study is finally here!
🔬 First DB RCT evaluating rivaroxaban in cirrhosis
💡 Complication-free survival benefit in moderate liver dysfunction—Child‑Pugh B7 (HR 0.26 [95 % CI 0.07–0.90]).
⚠️ Mild bleeding ↑, but no increase in severe events.
📄 www.journal-of-hepatology.eu/article/S016...

Another piece of evidence about the role of anticoagulants in cirrhosis. Results of a multicenter effort. The cirroxaban study. @hospitalclinic.bsky.social @idibaps.bsky.social @jhepatology.bsky.social

kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...

New publication from the EASL AI Task Force This paper is more than a review: it is a consensus report by a group of 34 leading international experts in hepatology, data science, and artificial intelligen

What are the latest and concrete recommendations for the clinical application of AI in hepatology?🤖

Read now this position paper from the EASL AI Task Force from @jhepatology.bsky.social: easl.eu/news/new-pub...

#LiverSky

Fear of Biopsying...Liver Lesions

😀Nice review on evaluating L1-RADS 3 & 4 lesions:
www.gastrojournal.org/article/S001...

🤔How fearful should we be of tumor seeding from biopsies?

👍Apparently much less frequent than we thought..

Reassuring

#Gastrosky #Liversky

Jaume Bosch

No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx.

Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top.

RIP

#liversky

Illustration showing Functional Venous Insufficiency and Venous Hypertension. Along left side of image reads the following: Clinical Practice Nonsurgical Management of Chronic Venous Insufficiency Eri Fukaya, M.D., Ph.D., and Raghu Kolluri, M.D. Published December 18, 2024

Chronic venous insufficiency is mainly due to venous hypertension, the cause of which can be structural or functional. Treatment is aimed at decreasing venous hypertension through conservative, nonprocedural management.

Learn more in this December 2024 Clinical Practice article: nej.md/41Zd5Av

Adeu Jaume! Everything you taught us stay with us, and your beloved unit will carry on with the same spirit!Thank you for so many things🌹

REMEMBERING PROFESSOR JAUME BOSCH
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.

A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.

Rest in peace, Jaime

I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social

Drs. @LukasHARTL and @MarleneHINTERSTEININGER of @meduniwien.ac.at showed in @CGH @AGA that
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD

📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social

📖 July Editor's Essential Reading presents: Point-of-Care Ultrasound in #Gastroenterology and #Hepatology

🔗 ow.ly/poXQ50WfJcx

🚨 #LiverSky
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta

Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org

@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social